Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety

BACKGROUND/AIMS: The treatment with daclatasvir plus asunaprevir (DCV+ASV) is associated with potent antiviral effects in patients with genotype 1b hepatitis C virus (HCV) infection. We investigated the real-world efficacy, changes in liver stiffness and noninvasive fibrosis markers, and the safety...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Gut Liver
Glavni autori: Lee, Hye Won, Oh, Se Rim, Kim, Dong Yun, Jeong, Yechan, Kim, Seungtaek, Kim, Beom Kyung, Kim, Seung Up, Kim, Do Young, Ahn, Sang Hoon, Han, Kwang-Hyub, Park, Jun Yong
Format: Artigo
Jezik:Inglês
Izdano: Editorial Office of Gut and Liver 2018
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5945264/
https://ncbi.nlm.nih.gov/pubmed/29409309
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5009/gnl17298
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items